Tuesday, April 16, 2024

TOPICS

Home Tags EpiVax Inc.

Tag: EpiVax Inc.

PBN announces 2020 Fastest Growing & Innovative Companies

PROVIDENCE – Twenty local companies are among the highest earners on Providence Business News’ list of Fastest Growing Private Companies, and 13 companies are...
EPIVAX is collaborating with the University of Georgia's vaccine expert Ted Ross, director of the Center for Vaccines and Immunology, to develop a novel coronavirus vaccine.

EpiVax announces collaboration on COVID-19 vaccine project

PROVIDENCE – EpiVax Inc. announced a collaboration with the University of Georgia’s vaccine expert Ted Ross, director, Center for Vaccines and Immunology, to accelerate...
STAYING PUT: Adam Anderson, owner of landscape architecture firm Design Under Sky and a Wavemaker fellow, stands near the remnants of his “10,000 Suns” sunflower installation in Providence. Anderson is still paying off his student loans and says the Wavemaker program is one of the factors that kept him in Rhode Island.  / PBN PHOTO/MIKE SKORSKI

STEM-ing the flow: Is R.I.’s Wavemaker program reducing ‘brain drain’?

Architectural designer Kaitlin DeGregorio was weighing a job offer in New York 2½ years ago when she instead made a commitment to a construction...
STEADY GROWTH: Nancy Parker Wilson, owner of Greenvale Vineyard in Portsmouth, with her son Bill Wilson, the operations manager. Parker Wilson says the vineyard has seen steady growth in its seasonal tasting and events business, a function of increasing interest in agritourism and the “eat local” movement. / PBN PHOTO/TRACY JENKINS

PBN survey: In election year, more R.I. companies say no to...

Rhode Island businesspeople have revived their optimism about the future of the state economy, but they appear reluctant to back up their improved outlook...
EPIVAX SAYS it is in search of partners and funding to help make a coronavirus vaccine that the Providence company says it has designed.

EpiVax seeks funding, partners for coronavirus vaccine

PROVIDENCE - EpiVax Inc., a Providence-based vaccine design company, says it has formulated a coronavirus vaccine, and is in search of funding and partners...
BRAINSTORMING: New England Medical Innovation Center founders and managing partners Aidan Petrie, left, and Lydia Shin Schroter, second from left, lead a brainstorming session with staff members Danielle Sturm, second from right, marketing and communications manager, and Maey Petrie, program coordinator, at the organization’s Providence office.
 / PBN PHOTO/MIKE SKORSKI

R.I.’s medtech innovators get much-needed support

Fresh ideas are at the core of the medical-technology industry, but as Aidan Petrie saw during his tenure as chief innovation officer at Providence-based...
IMMUNOLOGY ADVANCES: Dr. Anne S. De Groot, CEO, and William Martin, chief operating and information officer, co-founded biotech company EpiVax, which has made advances in computational immunology – a branch of medicine covering the human immune system – genomics and vaccine design.
 / PBN PHOTO/MICHAEL SALERNO

EpiVax on cutting edge of research

EpiVax Inc.’s motto is “science without fear.” From its new headquarters in the Rising Sun Mills complex, a former wool mill in Olneyville, the privately...
EPIVAX WILL celebrate its 20th anniversary in a new Olneyville office at 166 Valley St. June 15.

EpiVax moves growing staff to Olneyville

PROVIDENCE — Immunology engineering biotech firm EpiVax Inc. continues an eventful anniversary year with a new headquarters at 188 Valley St. in the Rising...
IMMUNOLOGY ENGINEERING BIOTECH firm EpiVax will use Small Business Innovation Research funding to develop a Tregitrope-biotherapeutic intended to restore immunological balance in Graves’ disease patients.

New EpiVax innovation could target Graves’ disease

PROVIDENCE — The first target of immunology engineering biotech firm EpiVax Inc.’s latest antigen-specific therapies? Graves’ disease, an auto-immune condition that results in hypothyroidism. Current...
TEAM MEETING: From left, Brenton DeBoef, professor of chemistry at the University of Rhode Island, and Alcinous Pharmaceutical team members Nicholas DaSilva, CEO and Ph.D. student in the URI College of Pharmacy; Benjamin Barlock, chief technology officer and Ph.D. student in the URI College of Pharmacy; David Worthen, chief operations officer and URI assistant professor in the Department of Biomedical and Pharmaceutical Sciences and the Department of Chemical Engineering; and Ken Rose, chief scientific officer and Ph.D. student in the URI College of Pharmacy, discuss Alcinous’ latest research project. / PBN PHOTO/RUPERT WHITELEY

Alcinous to use $50K Innovation Voucher to create new PARP inhibitor

Five weeks prior to celebrating its first year in business, Alcinous Pharmaceuticals received a $50,000 Innovation Voucher from R.I. Commerce Corp. The microcompany had been...
- Featured Event -

Latest News